Conceptos Categóricos

Crónicas de autores

Mara Medeiros *

Autora invitada por SIIC

El trabajo proporciona información sobre la seguridad y eficacia de la conversión de micofenolato de mofetilo a micofenolato sódico con capa entérica.

EFICACIA Y SEGURIDAD DE DOS FORMULACIONES DE ACIDO MICOFENOLICO EN NIÑOS CON TRASPLANTE RENAL

La conversión de micofenolato de mofetilo a mcofenolato sódico con capa entérica es eficaz y segura en niños con trasplante renal. Los síntomas gastrointestinales son menores con la formulación de capa entérica.

*Mara Medeiros
describe para SIIC los aspectos relevantes de su trabajo
EFICACY AND SAFETY OF CONVERSION OF MYCOPHENOLATE MOFETIL TO ENTERIC-COATED MYCOPHENOLATE SODIUM IN MEXICAN RENAL TRANSPLANT CHILDREN
Pediatric Transplantation,
14(6):746-752 Sep, 2010

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Hospital Infantil de México Federico Gómez, México, México
Imprimir nota
Referencias bibliográficas
Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80:S181-90, 2005.
Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 9:780-7, 2005.
Laouad I, Halimi JM, Buchler M, Al-Najjar A, Chatelet V, Nivet H et al. Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: analysis of long-term follow-up in renal transplantation. Transplantation 80:872-4, 2005.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13-58, 2007.
Hesselink DA, Van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 78:317-21, 2005.
Van Hest RM, Mathot RA, Vulto AG, Ijzermans JN, Van Gelder T. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther Drug Monit 28:31-4, 2006.
Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759-68, 2002.
Bremer S, Vethe NT, Rootwelt H, Bergan S. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol 9:173-80, 2009.
Sombogaard F, Peeters AM, Baan CC, Mathot RA, Quaedackers ME, Vulto AG et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 31:549-56, 2009.
Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 84:1443-51, 2007.
Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24:645-63, 2001.
Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80:S244-53, 2005.
Nart A, Sipahi S, Aykas A, Uslu A, Hoscoskun C, Toz H. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. Transplant Proc 40:189-92, 2008.
United States Patent. Patent Number 6,306,900 B1. Enteric coated pharmaceutical compositions. Available from: www.google.com.mx/patents?id=DA8IAAAAEBAJ&printsec=claims&zoom#v=onepage&q=&f=false. Accesed January, 25, 2010.
Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 66:103-11, 2006.
Zimmerhackl LB, Jungraithmayr T, Wiesmayr S, Filler G. Myfortic in pediatric transplantation. Pediatr Transplant 12:614-6, 2008.
Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 12:640-2, 2008.
Niaudet P, Charbit M, Loirat C, Lapeyraque AL, Tsimaratos M, Cailliez M et al. Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. Pediatr Nephrol 24:395-402, 2009.
Machnicki G, Pefaur J, Gaite L, Linchenco AM, Raimondi C, Schiavelli R et al. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort. Health Qual Life Outcomes 6:53, 2008.
Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol 22:1839-48, 2007.
Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353:2342-51, 2005.
Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753-60, 2008.
Ferraris JR, Tambutti ML, Prigoshin N, Grosman M, Cardoni RL. Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: Higher mycophenolic acid predose level but no changes in the immune biomarkers. Pediatr Transplant 2009.
Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transplant 2008.
Heller T, Geide A, Bonitz U, Wegner U, Grone HJ, Armstrong VW et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation 85:739-47, 2008.
Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 85:1120-4, 2008.
Budde K, Tedesco-Silva H, Pestana JM, Glander P, Neumayer HH, Felipe CR et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 29:381-4, 2007.
Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85:1675-85, 2008.
Bunnapradist S, Lentine KL, Burroughs TE, Pinsky BW, Hardinger KL, Brennan DC et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82:102-7, 2006.
Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 22:2440-8, 2007.
Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 39:88-93, 2007.
Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 31:542-8, 2009.
Otros artículos de Mara Medeiros

Medeiros DM, Gómez AC, Urizar JP, Campos Sepúlveda AE, Saldaña IM, Ramírez LE, Romero NB, Velásquez JLF, Castañeda Hernández G, Muñoz AR. Bioavailability of two oral formulations of cyclosporin A in uremic children before renal transplantation. Pediatr Transplantation2:145-149, 1998.
Medeiros DM, Pérez Urizar J, Muñoz AR, Castañeda Hernández G. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either sandimmun or neoral cyclosporine. Pediatr Transplantation 3:225-230, 1999.
Medeiros M, Sharma VK, Ding R, Yamaji K, Li B, Muthukumar T, Valverde-Rosas S, Hernández AM, Muñoz R, Suthanthiran M. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNA later. J Immunol Methods 279:135-142, 2003.
Muthukumar T, Ding R, Dadhania D, Medeiros M, Li B, Sharma VK, Hartono C, Serur D, Seshan SV, Volk HD, Reinke P, Kapur S, Sutanthiran M. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acuite rejection of renal allografts. Transplantation 75:1565-1570, 2003.
Medeiros M, Pérez Urizar J, Mejía Gaviria N, Ramírez López E, Castañeda Hernández G, Muñoz R. Decreased cyclosporine exposure during the remission of nephrotic syndrome. Pediatr Nephrol 22:84-90, 2007.
Medeiros M, Pérez Urizar J, Pedraza Chaverri J, Muñoz R, Castañeda Hernández G. Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats . Can J Physiol and Pharm 85:502-506, 2007.
Medeiros M, Alberu J, García GR, Fuentes Y, Velásquez L. Virus polioma en trasplante renal. Nefrologia 28(2):203-211, 2008.
Ramírez Cortás G, Fuentes Velasco Y, García Roca P, Guadarrama O, López M, Valverde Rosas S, Velásquez Jones L, Romero B, Toussaint G, Medeiros M. Prevalence of metabolic syndrome and obesity in renal transplanted Mexican children. Pediatr Transplantation 13:579-574, 2009.
Suthanthiran M, Gerber L, Schwartz J, Sharma V, Medeiros M, Marion RM, Pickering T, August P. Circulating transfoming growth factor b1 levels and the risk for kidney disease in African Americans. Kidney Int 76:72-80, 2009.
Esquivel A, González Ramírez J, Alberú J, Gracida C, Medeiros M, Castañeda Hernández G. Comparisson of dissolution properties of 2 enteric-coated formulations containing mycophenolate sodium: Myfortic vs. Femulan. Transplant Proc 42:353-356, 2010.

Para comunicarse con Mara Medeiros mencionar a SIIC como referencia:
medeiro.mara@gmail.com

Autora invitada
30 de septiembre, 2010
Descripción aprobada
9 de noviembre, 2010
Reedición siicsalud
7 de junio, 2011

Acerca del trabajo completo
EFICACIA Y SEGURIDAD DE DOS FORMULACIONES DE ACIDO MICOFENOLICO EN NIÑOS CON TRASPLANTE RENAL

Título original en castellano
EFICACIA Y SEGURIDAD DE LA CONVERSION DE MICOFENOLATO DE MOFETILO A MICOFENOLATO SODICO CON CAPA ENTERICA EN NIÑOS MEXICANOS CON TRASPLANTE RENAL

Autores
Mara Medeiros1, Herlinda Reyes2, Ana María Hernández3, Saúl Valverde4
1 Dra., Laboratorio de Investigación en Nefrologia y Metabolismo Mineral, Hospital Infantil de México Federico Gómez, México, México
2 Maestra en Ciencias, Hospital Infantil de México Federico Gómez, México, México, Químico A
3 Bióloga, Hospital Infantil de México Federico Gómez, México, Quimico B
4 Médico, Hospital Infantil de México Federico Gómez, México, Medico Especialista

Acceso a la fuente original
Pediatric Transplantation
http://www.blackwellpublishing.com/journals/PTR

El artículo se relaciona estrictamente con las especialidades de siicsalud
El artículo se conecta secundariamente con las especialidades
    


ua40317